Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.43 |
| ▸ | FPR1 | P21462 | 3/20 | 0.38 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044099 | 1.00 | P2RX7 (0.44) | P2RX7EPHX2FPR1FPR2DGAT2 | |
| SCHEMBL5047120 | 0.91 | P2RX7 (0.42) | P2RX7EPHX2FPR1FPR2DGAT2 | |
| SCHEMBL5047127 | 0.91 | P2RX7 (0.42) | P2RX7EPHX2FPR1FPR2DGAT2 | |
| SCHEMBL5043577 | 0.90 | DGAT2 (0.39) | FPR1FPR2DGAT2TRPV1LMNA | |
| SCHEMBL5043572 | 0.90 | DGAT2 (0.39) | FPR1FPR2DGAT2TRPV1LMNA | |
| SCHEMBL5041232 | 0.88 | P2RX7 (0.43) | P2RX7EPHX2FPR1FPR2DGAT2 | |
| SCHEMBL5041238 | 0.88 | P2RX7 (0.43) | P2RX7EPHX2FPR1FPR2DGAT2 | |
| SCHEMBL5041193 | 0.84 | PKM (0.43) | EPHX2FPR1FPR2 | |
| SCHEMBL5041197 | 0.84 | PKM (0.43) | EPHX2FPR1FPR2 | |
| SCHEMBL5040874 | 0.83 | ENPP2 (0.42) | EPHX2DGAT2TRPV1KCNH2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | P2RX7 187/4885EPHX2 1557/4885FPR1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.